{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '7.1.1.', 'Medical Devices', 'The GSK ELLIPTA medical device will be provided for use in this study.', 'The other medical device (not manufactured by or for GSK provided) for use in this', 'study is the Handihaler.', 'GSK medical device incidents, including those resulting from malfunctions of the', 'device, must be detected, documented, and reported by the investigator throughout', 'the study. (see Section 9.2.10).', '7.2.', 'Dose Modification', 'No dose modifications are planned for this study.', '7.3.', 'Method of Treatment Assignment', 'Participants will be assigned to study treatment in accordance with the randomisation', 'schedule. The randomisation code will be generated by using a validated computerised', 'system. Participants will be randomised using an Interactive Web Response System', '(IWRS). The study will use central-based randomisation to allocate treatments. Once a', 'randomisation number is assigned to a participant it cannot be reassigned to any other', 'participant in the study.', '7.4.', 'Blinding', 'This will be a double-blind study and the following will apply.', \"The Investigator or treating physician may unblind a participant's treatment\", 'assignment only in the case of an emergency OR in the event of a serious', 'medical condition when knowledge of the study treatment is essential for the', 'appropriate clinical management or welfare of the participant as judged by the', 'Investigator.', \"Investigators have direct access to the participant's individual study treatment.\", 'It is preferred (but not required) that the Investigator first contacts the Medical', 'Monitor or appropriate GSK study personnel to discuss options before unblinding', \"the participant's treatment assignment.\", 'If GSK personnel are not contacted before the unblinding, the Investigator must', 'notify GSK within 24 hours after unblinding, but without revealing the treatment', 'assignment of the unblinded participant, unless that information is important for', 'the safety of participants currently in the study.', 'The date and event or condition which led to the unblinding (i.e. the primary', 'reason) will be recorded in source documentation and in the eCRF.', \"Should a participant's treatment assignment be unblinded then the participant may\", 'continue the assigned study treatment and be followed-up as per protocol until the', 'completion of the Safety Follow-up assessments.', '51']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', \"GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the\", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', \"report, identifying the participant's treatment assignment, may be sent to Investigators in\", 'accordance with local regulations and/or GSK policy. Participants will not be withdrawn', 'from the study.', 'Masking of tiotropium and placebo to tiotropium capsules', 'This study will use a double-dummy design for dosing, whereby participants will be', 'given two inhalers (ELLIPTA and Handihaler). All participants and site personnel', 'involved in efficacy and safety assessments will be blinded to assigned treatment during', 'the study. Tiotropium capsules have trade markings that are not present on the placebo', 'capsules. This study has a parallel-group design which ensures the capsule type will be', 'consistent for each participant for the duration of the study. In addition, tiotropium and', 'placebo capsules will be closely matched in colour. Both the tiotropium and placebo', 'blister packages will be covered with opaque over-labels with the intent of hiding the', 'information on the tiotropium packaging. The HandiHaler dry powder inhalers will be', 'covered with labels to mask identifying marks on the inhaler. Investigator and site', 'personnel involved in efficacy and safety assessments will be instructed not be present', 'when a participant administers his/her study medication at clinic visits, to guard against', 'the possibility of personnel involved in the collection of efficacy and safety data,', 'identifying the capsules removed from the blisters. Sites are required to have study', 'treatment dosed, dispensed and accounted for by site personnel that are not involved in', 'any efficacy or safety assessments.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The Investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study treatment received and any discrepancies are', 'reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only authorized', 'site staff may supply or administer study treatment. All study treatments must be stored', 'in a secure, environmentally controlled, and monitored (manual or automated) area in', 'accordance with the labeled storage conditions with access limited to the Investigator and', 'authorized site staff.', 'The Investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study treatment accountability, reconciliation, and record maintenance (ie,', 'receipt, reconciliation, and final disposition records).', 'Further guidance and information for the final disposition of unused study treatment are', 'provided in the Study Reference Manual (SRM).', 'Under normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. Take adequate precautions to avoid direct eye', 'or skin contact and the generation of aerosols or mists. In the case of unintentional', 'occupations exposure notify the monitor, Medical Monitor and/or GSK study contact.', '52']\n\n###\n\n", "completion": "END"}